Trial Profile
PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 18 Jun 2020 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 1 Jul 2019 to 15 Feb 2020.
- 18 Feb 2019 Planned End Date changed from 1 Feb 2019 to 1 Jul 2019.